[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.92.62. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Viewpoint
October 2014

Human Papillomavirus Testing for Primary Cervical Cancer ScreeningIs It Time to Abandon Papanicolaou Testing?

Author Affiliations
  • 1Division of Gynecologic Oncology, Brigham and Women’s Hospital, Boston, Massachusetts
  • 2Harvard Medical School, Boston, Massachusetts
JAMA Intern Med. 2014;174(10):1539-1540. doi:10.1001/jamainternmed.2014.4021

In the 1920s, when George Papanicolaou began to develop the screening test that now bears his name, the cause of cervical cancer was not known, and the cancer was a common cause of death among women. Since Papanicolaou testing entered clinical practice in the 1950s, however, cervical cancer incidence and mortality have markedly decreased in the United States. In 2014, there will be an estimated 12 360 new cases of cervical cancer and 4020 deaths attributable to the disease.1

First Page Preview View Large
First page PDF preview
First page PDF preview
×